First Mercantile Trust’s CRISPR Therapeutics CRSP Stock Holding History

First Mercantile Trust’s Portfolio CRSP Stock Details CRSP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q2	–	Sell	-3,158	Closed	-$134K	–	869
2020 Q1	$134K	Buy	3,158 +1,273	+68%	+$65.7K	0.02%	467
2019 Q4	$115K	Buy	+1,885	New	+$103K	0.01%	642
2018 Q3	–	Sell	-2,401	Closed	-$141K	–	919
2018 Q2	$141K	Buy	+2,401	New	+$137K	0.03%	616

Other funds holding CRSP

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

VVM

Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

WRF

Waddell & Reed Financial Overland Park, Kansas $48.6B AUM 84.78% 1-Year Est. Return

First Mercantile Trust's CRSP Position: Q2 2020 in Review

First Mercantile Trust sold out of CRISPR Therapeutics (CRSP) in Q2 2020, closing a stake of 3,158 shares — an estimated $134K sold.

First Mercantile Trust first reported a position in CRSP in Q2 2018 and held it in 3 quarters. The position peaked at $141K in Q2 2018. 276 funds tracked by Wall St. Rank hold CRSP as of Q2 2020.

First Mercantile Trust reported no remaining CRISPR Therapeutics position as of Q2 2020 after selling out during the quarter.
First Mercantile Trust sold 3,158 CRISPR Therapeutics shares in Q2 2020, an estimated $134K.
First Mercantile Trust first reported a position in CRISPR Therapeutics in Q2 2018 and held it in 3 quarters.
First Mercantile Trust's CRISPR Therapeutics position peaked at $141K in Q2 2018.
276 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q2 2020.

Based on First Mercantile Trust's 13F filing for Q2 2020, filed 10 Aug 2020.